Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Correspondence
  • Published:

Imatinib mesylate (GleevecTM) reduces phlebotomy requirements in polycythemia vera

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Silver, R. Imatinib mesylate (GleevecTM) reduces phlebotomy requirements in polycythemia vera. Leukemia 17, 1186–1187 (2003). https://doi.org/10.1038/sj.leu.2402938

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402938

This article is cited by

Search

Quick links